Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by C. Mueller
Brothers sentenced for child exploitation offenses involving electronic communications
Ryan Ellison, U.S. Attorney for the District of New Mexico | Department of Justice Ryan Ellison, U.S. Attorney for the District of New Mexico | Department of Justice Two brothers have been sentenced for sexually abusing a minor, with one receiving 204 months in prison and the other 135 months. The sentencing took place in Albuquerque, New Mexico. Federal authorities stated that there is no parole in the federal system.
Neuropilin-1 Expression on CD4 T Cells Is Atherogenic and Facilitates T Cell Migration to the Aorta in Atherosclerosis
Dalia E. Gaddis, Lindsey E. Padgett, Runpei Wu and Catherine C. Hedrick J Immunol December 15, 2019, 203 (12) 3237-3246; DOI: https://doi.org/10.4049/jimmunol.1900245 Key Points Western diet feeding increases Nrp1 on Foxp3− CD4 T cells in ApoE−/− mice. Nrp1+Foxp3− CD4 T cells are highly proliferative and atherogenic. Nrp1+Foxp3− CD4 T cells preferentially migrate to the aorta and PaLN.
Fluorination in thieno[3,4-c]pyrrole-4,6-dione copolymers leading to electron transport, high crystallinity and end-on alignment
A series of copolymers based on thieno[3,4-c]pyrrole-4,6-dione and thiophene-phenyl-thiophene with varying degrees of fluorination on the phenyl unit was synthesized by Stille polycondensation. The influence of the degree of fluorination on the optical, thermal and electrochemical properties of these polymers is systematically studied. Additionally, the charge transport in organic field effect transistors (OFETs) as well as the thin film alignment are investigated.
47TiPTACTI-mel (Two ACTive Immunotherapeutics in melanoma): A Phase 1 trial in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab
47TiPTACTI-mel (Two ACTive Immunotherapeutics in melanoma): A Phase 1 trial in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab C. Mueller1 and F.
46TiPAIPAC (Active Immunotherapy PAClitaxel): A phase IIb trial in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy regimen of paclitaxel
Aim/Background: This ongoing Phase IIb clinical trial aims to investigate the safety and efficacy of the active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. IMP321 consists of the extracellular portion of the human lymphocyte activation gene 3 (LAG-3) protein fused to the Fc fraction of a human IgG1.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with C.
Contact C., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack